Greenwich LifeSciences, Inc. (GLSI)Healthcare | Biotechnology | Stafford, United States | NasdaqCM
24.06 USD
+1.03
(4.472%)
⇧
(June 12, 2026, 4 p.m.
EDT)
After hours: 23.98 -0.08 (-0.080%) ⇩ (June 12, 2026, 5:06 p.m. EDT) |
Hot Take ↕ | June 7, 2026, 5:19 a.m. EDT
The immediate outlook is neutral-to-slightly-bearish despite a recent bounce, as the stock trades at a significant discount to its 50-day moving average and carries a heavy short interest that suggests lingering skepticism. While the price has recovered from multi-year lows, the underlying business fundamentals are severely compromised by negative earnings, negative free cash flow, and a massive price-to-book ratio that indicates the market views the company as a distressed asset rather than a viable enterprise. The recent news cycle highlights critical operational hurdles, including audit delays, widening losses, and regulatory notices regarding late filings, which create substantial uncertainty for any near-term catalyst. Furthermore, the company has no history of paying dividends, offering no income floor to offset the high volatility and execution risks inherent in a biotech firm struggling with clinical trial side effects and capital raising needs. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.080132 |
| AutoTheta | 0.080477 |
| MSTL_105 | 0.082521 |
| AutoARIMA | 0.083707 |
| AutoETS | 0.083947 |
| MSTL_74 | 0.176758 |
| MSTL_74_105 | 0.198943 |
Forecast horizon: 60 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 0.65 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.329 |
| Excess Kurtosis | -0.94 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 353,157,664 |
| Forward P/E | -29.34 |
| Beta | 1.38 |
| Website | https://greenwichlifesciences.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.6152174 |
| Address1 | Building 14 |
| Address2 | 3,992 Bluebonnet Dr. |
| All Time High | 158.07 |
| All Time Low | 3.262 |
| Ask | 29.76 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 175,870 |
| Average Daily Volume3 Month | 151,647 |
| Average Volume | 151,647 |
| Average Volume10Days | 175,870 |
| Beta | 1.377 |
| Bid | 17.13 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 0.359 |
| City | Stafford |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 24.06 |
| Current Ratio | 2.007 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,780,012,800 |
| Day High | 24.38 |
| Day Low | 23.18 |
| Display Name | Greenwich LifeSciences |
| Earnings Timestamp End | 1,786,651,200 |
| Earnings Timestamp Start | 1,786,651,200 |
| Ebitda | -22,403,600 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -15.295 |
| Enterprise Value | 342,652,256 |
| Eps Forward | -0.82 |
| Eps Trailing Twelve Months | -1.61 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 24.7549 |
| Fifty Day Average Change | -0.6949005 |
| Fifty Day Average Change Percent | -0.02807123 |
| Fifty Two Week Change Percent | 161.52174 |
| Fifty Two Week High | 34.1 |
| Fifty Two Week High Change | -10.039999 |
| Fifty Two Week High Change Percent | -0.29442814 |
| Fifty Two Week Low | 7.78 |
| Fifty Two Week Low Change | 16.279999 |
| Fifty Two Week Low Change Percent | 2.0925448 |
| Fifty Two Week Range | 7.78 - 34.1 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,601,040,600,000 |
| Float Shares | 7,388,863 |
| Forward Eps | -0.82 |
| Forward P E | -29.341463 |
| Free Cashflow | -3,402,170 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,780,531,200 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.47861 |
| Held Percent Institutions | 0.124239996 |
| Implied Shares Outstanding | 14,678,208 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas. |
| Long Name | Greenwich LifeSciences, Inc. |
| Market | us_market |
| Market Cap | 353,157,664 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_653283398 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -22,270,576 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 353,157,684 |
| Number Of Analyst Opinions | 2 |
| Open | 23.18 |
| Operating Cashflow | -12,781,497 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 832-819-3232 |
| Post Market Change | -0.07999992 |
| Post Market Change Percent | -0.33250177 |
| Post Market Price | 23.98 |
| Post Market Time | 1,781,298,375 |
| Previous Close | 23.03 |
| Price Hint | 2 |
| Price To Book | 67.0195 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.007 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 1.03 |
| Regular Market Change Percent | 4.47242 |
| Regular Market Day High | 24.38 |
| Regular Market Day Low | 23.18 |
| Regular Market Day Range | 23.18 - 24.38 |
| Regular Market Open | 23.18 |
| Regular Market Previous Close | 23.03 |
| Regular Market Price | 24.06 |
| Regular Market Time | 1,781,294,401 |
| Regular Market Volume | 94,363 |
| Return On Assets | -2.11267 |
| Return On Equity | -6.76658 |
| Sand P52 Week Change | 0.23177934 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 14,678,208 |
| Shares Percent Shares Out | 0.1034 |
| Shares Short | 1,518,228 |
| Shares Short Previous Month Date | 1,777,507,200 |
| Shares Short Prior Month | 1,544,439 |
| Short Name | Greenwich LifeSciences, Inc. |
| Short Percent Of Float | 0.1984 |
| Short Ratio | 11.85 |
| Source Interval | 15 |
| State | TX |
| Symbol | GLSI |
| Target High Price | 50.0 |
| Target Low Price | 45.0 |
| Target Mean Price | 47.5 |
| Target Median Price | 47.5 |
| Total Cash | 10,505,435 |
| Total Cash Per Share | 0.716 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.61 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 18.963776 |
| Two Hundred Day Average Change | 5.096224 |
| Two Hundred Day Average Change Percent | 0.26873466 |
| Type Disp | Equity |
| Volume | 94,363 |
| Website | https://greenwichlifesciences.com |
| Zip | 77,477 |